All In Biotech

Drug Trial Radar · NCT07432958

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Feb 25, 2026

Primary completion

Sep 3, 2027

Study completion Jan 3, 2028

Sponsor

Lead sponsor
Appello Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Conditions

  • Parkinson Disease

Interventions

  • AP-472Drug

    Oral tablet

  • PlaceboOther

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in average daily OFF time on motor diaries for AP-472 compared to placebo (normalized to 16-hour awake time)Time frame: Week 12

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences (Site #208)

    Little Rock, Arkansas · Recruiting

  • Profound Research LLC (Site #222)

    Carlsbad, California · Recruiting

  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)

    Los Alamitos, California · Recruiting

  • Keck Medicine of USC - USC Healthcare Center 2 (Site #221)

    Los Angeles, California · Recruiting

  • Parkinson's Research Centers of America (Site #218)

    Palo Alto, California · Recruiting

  • Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)

    Englewood, Colorado · Recruiting

  • Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)

    Boca Raton, Florida · Recruiting

  • UM-UHealth at Boca Raton (Site #226)

    Boca Raton, Florida · Recruiting

  • Velocity Clinical Research - Hallandale Beach (Site #228)

    Hallandale, Florida · Recruiting

  • University of Miami (Site #220)

    Miami, Florida · Recruiting

  • Neurology One (Site #205)

    Orlando, Florida · Recruiting

  • USF Parkinson's Disease and Movement Disorders Center (Site #206)

    Tampa, Florida · Recruiting

  • Augusta University Medical Center (Site #212)

    Augusta, Georgia · Recruiting

  • Josephson Wallack Munshower Neurology PC (Site #231)

    Indianapolis, Indiana · Recruiting

  • The University of Kansas (KU) (Site #216)

    Kansas City, Kansas · Recruiting

  • Kentucky Neuroscience Institute (Site #213)

    Lexington, Kentucky · Recruiting

  • Beth Israel Deaconess Medical Center (Site #211)

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System (UMHS) (Site #202)

    Ann Arbor, Michigan · Recruiting

  • Quest Research Institute - Alcanza - PPDS (Site #201)

    Farmington Hills, Michigan · Recruiting

  • University of New Mexico Health Sciences Center (Site #225)

    Albuquerque, New Mexico · Recruiting

  • Joan and Sanford I. Weill Department of Medicine (Site #224)

    New York, New York · Recruiting

  • Mount Sinai School of Medicine (Site #209)

    New York, New York · Recruiting

  • Asheville Neurology Specialists, P.A. (Site #229)

    Asheville, North Carolina · Recruiting

  • Duke Neurological Disorders Clinic (Site #210)

    Durham, North Carolina · Recruiting

  • Cleveland Clinic (Site #223)

    Cleveland, Ohio · Recruiting

  • The Ohio State University Wexner Medical Center (site #207)

    Columbus, Ohio · Recruiting

  • Vanderbilt University Medical Center (Site #204)

    Nashville, Tennessee · Recruiting

  • Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)

    Cypress, Texas · Recruiting

  • Central Texas Neurology Consultants (Site #203)

    Round Rock, Texas · Recruiting

  • EvergreenHealth (Site #219)

    Kirkland, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.